down arrow

Hybio Pharmaceutical Co.. Ltd.

  • Market Cap: Large Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CNE1000011T7
  • SHE: 300199
CNY
24.29
0.44 (1.84%)

Sep 23

SHE

 View all stocks in this country
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Hybio Pharmaceutical Co.. Ltd.

Why is Hybio Pharmaceutical Co.. Ltd. ?

1
With a growth in Operating Profit of 179.39%, the company declared Very Positive results in Mar 26
  • The company has declared positive results for the last 7 consecutive quarters
  • OPERATING CASH FLOW(Y) Highest at CNY 267.19 MM
  • ROCE(HY) Highest at 13.6%
  • RAW MATERIAL COST(Y) Fallen by -25.74% (YoY)
2
With ROE of 12.39%, it has a fair valuation with a 18.48 Price to Book Value
  • Over the past year, while the stock has generated a return of 37.40%, its profits have risen by 195.4% ; the PEG ratio of the company is 0.8
3
Consistent Returns over the last 3 years
  • Along with generating 37.40% returns in the last 1 year, the stock has outperformed China Shanghai Composite in each of the last 3 annual periods
stock-recommendationReal-Time Research Report

Verdict Report

How much should you buy?

  1. Overall Portfolio exposure to Hybio Pharmaceutical Co.. Ltd. should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Hybio Pharmaceutical Co.. Ltd. for you?

High Risk, High Return

Absolute
Risk Adjusted
Volatility
Hybio Pharmaceutical Co.. Ltd.
4.74%
2.31
58.68%
China Shanghai Composite
3.0%
1.20
14.07%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
6.36%
EBIT Growth (5y)
18.11%
EBIT to Interest (avg)
-1.51
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
2.65
Sales to Capital Employed (avg)
0.26
Tax Ratio
41.28%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
1.28%
ROE (avg)
0.88%
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
190
Industry P/E
Price to Book Value
23.56
EV to EBIT
115.47
EV to EBITDA
70.75
EV to Capital Employed
7.40
EV to Sales
20.25
PEG Ratio
0.97
Dividend Yield
NA
ROCE (Latest)
6.41%
ROE (Latest)
12.39%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Mildly Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
No Trend
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

31What is working for the Company
OPERATING CASH FLOW(Y)

Highest at CNY 388.76 MM

NET PROFIT(Q)

At CNY 108.96 MM has Grown at 361.54%

ROCE(HY)

Highest at 16.24%

DEBT-EQUITY RATIO (HY)

Lowest at 211.98 %

NET SALES(Q)

Highest at CNY 389.14 MM

OPERATING PROFIT(Q)

Highest at CNY 159.33 MM

PRE-TAX PROFIT(Q)

Highest at CNY 98.58 MM

-1What is not working for the Company
NO KEY NEGATIVE TRIGGERS

Here's what is working for Hybio Pharmaceutical Co.. Ltd.

Pre-Tax Profit
At CNY 98.58 MM has Grown at 397.02%
over average net sales of the previous four periods of CNY 19.83 MM
MOJO Watch
Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (CNY MM)

Net Profit
At CNY 108.96 MM has Grown at 361.54%
over average net sales of the previous four periods of CNY 23.61 MM
MOJO Watch
Near term Net Profit trend is very positive

Net Profit (CNY MM)

Operating Cash Flow
Highest at CNY 388.76 MM and Grown
In each year in the last three years
MOJO Watch
The company has generated higher cash revenues from business operations

Operating Cash Flows (CNY MM)

Net Sales
At CNY 389.14 MM has Grown at 62.9%
over average net sales of the previous four periods of CNY 238.88 MM
MOJO Watch
Near term sales trend is very positive

Net Sales (CNY MM)

Net Sales
Highest at CNY 389.14 MM
in the last five periods
MOJO Watch
Near term sales trend is positive

Net Sales (CNY MM)

Operating Profit
Highest at CNY 159.33 MM
in the last five periods
MOJO Watch
Near term Operating Profit trend is positive

Operating Profit (CNY MM)

Pre-Tax Profit
Highest at CNY 98.58 MM
in the last five periods
MOJO Watch
Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (CNY MM)

Debt-Equity Ratio
Lowest at 211.98 %
in the last five Semi-Annual periods
MOJO Watch
The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Footer loading